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Abstract 
Background: Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chro-
matin organization and their tight associations with diseases including cancer and mental disorders. The first KDM 
inhibitors for KDM1 have entered clinical trials, and efforts are ongoing to develop potent, selective and cell-active 
‘probe’ molecules for this target class. Robust cellular assays to assess the specific engagement of KDM inhibitors 
in cells as well as their cellular selectivity are a prerequisite for the development of high-quality inhibitors. Here we 
describe the use of a high-content cellular immunofluorescence assay as a method for demonstrating target engage-
ment in cells.
Results: A panel of assays for the Jumonji C subfamily of KDMs was developed to encompass all major branches of 
the JmjC phylogenetic tree. These assays compare compound activity against wild-type KDM proteins to a catalyti-
cally inactive version of the KDM, in which residues involved in the active-site iron coordination are mutated to inacti-
vate the enzyme activity. These mutants are critical for assessing the specific effect of KDM inhibitors and for revealing 
indirect effects on histone methylation status. The reported assays make use of ectopically expressed demethylases, 
and we demonstrate their use to profile several recently identified classes of KDM inhibitors and their structurally 
matched inactive controls. The generated data correlate well with assay results assessing endogenous KDM inhibition 
and confirm the selectivity observed in biochemical assays with isolated enzymes. We find that both cellular perme-
ability and competition with 2-oxoglutarate affect the translation of biochemical activity to cellular inhibition.
Conclusions: High-content-based immunofluorescence assays have been established for eight KDM members 
of the 2-oxoglutarate-dependent oxygenases covering all major branches of the JmjC-KDM phylogenetic tree. The 
usage of both full-length, wild-type and catalytically inactive mutant ectopically expressed protein, as well as struc-
ture-matched inactive control compounds, allowed for detection of nonspecific effects causing changes in histone 
methylation as a result of compound toxicity. The developed assays offer a histone lysine demethylase family-wide 
tool for assessing KDM inhibitors for cell activity and on-target efficacy. In addition, the presented data may inform 
further studies to assess the cell-based activity of histone lysine methylation inhibitors.
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Background
Histones are highly conserved proteins that play impor-
tant roles, not only in compacting DNA in the cell, but 
which also have dynamic functions in many physiological 
and molecular processes. Covalent modifications of the 
histone tail, in particular on lysine residues, are an essen-
tial part of epigenetic mechanisms to regulate processes 
like DNA repair and gene transcription [1, 2]. The com-
plex code of histone tail modifications is tightly regulated 
and includes a variety of modifications, most prominently 
acetylation and methylation of lysine and arginine resi-
dues. Enzymes that modify or bind to these residues have 
been implicated in a variety of diseases including cancer, 
inflammatory diseases, heart disease and neurodegen-
erative diseases [3–5]. Methylation of histone lysines was 
once thought by many to be irreversible, but two classes 
of histone lysine demethylases (KDMs) have now been 
identified that catalyse the removal of these methylation 
marks. Based on their enzymatic mechanism, the flavin-
dependent demethylases of the KDM1 subfamily (lysine-
specific demethylases or LSDs) are distinguished from 
the Jumonji C (JmjC) family of KDMs, comprising the 
KDM2 to KDM7 subfamilies, which belong to the super-
family of Fe(II)- and 2-oxoglutarate (2-OG)-dependent 
oxygenases. Demethylation of different marks has been 
described thereby influencing the ratios of mono-, di- 
and tri-methylation on H3K4, H3K9, H3K27, H3K36 and 
H4K20, resulting in differential effects on gene transcrip-
tion. For example, H3K4me2/3 and H3K36me3 are pref-
erentially associated with transcriptionally active genes, 
while H3K9me2/3, H3K27me2/3 and H4K20me3 corre-
late with transcriptional repression [6–8].
There is growing interest in exploring the biology and 
disease relevance of the KDMs with the help of well-char-
acterized ‘probe molecules’ that show potent activity in 
biochemical and cellular assays as well as selectivity over 
other KDMs [9]. Several inhibitors for the KDM1 fam-
ily have been described, with the most advanced com-
pounds entering clinical trials [6]. A number of inhibitors 
have also recently been discovered for the JmjC family of 
demethylases, e.g. [6, 10–17]. In order to draw conclu-
sions regarding the biological activity of new inhibitors, it 
must first be confirmed that their observed cellular effect 
is due to the inhibition of the respective enzyme rather 
than uncharacterized off-target activity or nonspecific 
effects. We have developed and evaluated an immunoflu-
orescence-based high-content imaging assay to assess the 
on-target effect of demethylase inhibitors and describe 
here the lessons learned.
Results
Several robust in  vitro biochemical assays have been 
developed to assess the potency of potential KDM inhibi-
tors; however, most of them do not use the full-length 
protein, but rather employ truncated constructs encom-
passing mainly the catalytic domain. It has recently been 
shown that, in addition to the catalytic domain, reader 
domains, such as plant homeodomains (PHDs), are also 
important in overall KDM enzymatic activity [18, 19]. 
In order to assess the on-target effect of KDM inhibitors 
of the JmjC family in cells, we have developed a panel of 
high-content immunofluorescence-based assays cover-
ing the major branches of the phylogenetic tree of the 
JmjC family of 2-OG-dependent oxygenases that rely on 
the full-length protein (Fig. 1) [20]. The assays utilize an 
overexpression system after transiently transfecting the 
full-length FLAG-tagged demethylase (WT) into cells 
and assaying the cells overexpressing the demethylase for 
the respective substrate mark in a high-content immuno-
fluorescence (IF) assay. Overexpression was found to be 
optimal after 20–24  h for the tested demethylases after 
which cell death was observed, even in the absence of 
inhibitor (Yapp et  al., unpublished results). As control, 
catalytically inactive KDMs (MUT) were used, in which 
the specific residues involved in iron coordination were 
substituted for alanine residues (or tyrosine for KDM3A) 
(Additional file 1: Figure S1; Additional file 2: Table S1). 
In the ideal case, the dose–response curve of the ectopi-
cally produced WT KDM should meet the curve of the 
MUT KDM when the enzyme is fully inhibited by the 
inhibitor.
A global decrease in methylation was observed for 
HeLa cervical carcinoma cells overexpressing the WT 
demethylase as determined by reduction in the levels of 
methyl-lysine antibody staining (e.g. KDM5B overex-
pression correlating with H3K4me3 nuclear staining in 
Fig.  2a iv–vi), relative to cells overexpressing the corre-
sponding catalytically inactive MUT demethylase or non-
transfected cells (Fig. 2a vii–ix).
Many reported inhibitors for the JmjC-KDMs display poor 
cellular activity [6, 11, 13, 14], and prodrug strategies have 
been utilized in an attempt to enhance cellular permeabil-
ity and activity [6, 21–23]. We synthesized and tested vari-
ous inhibitors from our KDM inhibitor programme as well 
Keywords: Histone lysine demethylase, Chromatin, Immunofluorescence, Cell proliferation, Apoptosis, Toxicity, 
Epigenetics, 2-Oxoglutarate oxygenases
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as inhibitors described in the literature (Additional file  3: 
Figure S2). Recently, potent inhibitors of the KDM5 family 
with good cellular activity have been described by Epithera-
peutics (Table 1; Additional file 3: Figure S2; Additional file 4: 
Table S2) [24–26]. We tested two of the reported inhibitors: 
KDOAM-20 and KDOAM-21 (also known as KDM5-C49 
and KDM5-C70, respectively) [25], in our cellular high-
content assays quantifying changes in the global methylation 
levels 24 h after addition of the compound. The pyridine car-
boxylic acid KDOAM-20 is a highly potent KDM5 inhibitor 
in  vitro, whereas the more cell-active ethyl ester derivative 
KDOAM-21 most likely acts as prodrug, which is hydrolysed 
in cells to provide KDOAM-20, an approach utilized also in 
other carboxylic acid-bearing KDM inhibitor scaffolds and 
2-OG oxygenase inhibitors (Table 1) [21, 23, 27]. In parallel, 
we also tested a related control compound, KDOAM-32, in 
which the core scaffold has been modified to abrogate KDM-
binding (Table 1; Additional file 3: Figure S2).
HeLa cells transiently overexpressing WT KDM5B 
were treated with the ester KDOAM-21 for 24  h. At 
Fig. 1 Position of KDMs in phylogenetic tree of 2-OG-dependent oxygenases. a Phylogenetic tree of the catalytic domains of human 2-OG oxyge-
nases adapted according to [5]. The different subfamilies of KDMs are indicated. Non-KDM oxygenases are in grey. Proteins for which IF assays are 
described herein are highlighted in red. b Domain organization of 2-OG-dependent oxygenases for which IF assays are presented. The identities of 
the different domains are: JmjC Jumonji C domain, JmjN Jumonji N domain, PHD plant homeodomain, TDR tudor domain, C5HC2 zinc finger C5HC2 
type, LRR leucine-rich repeat, TCZ treble-clef zinc finger domain
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the highest compound concentration tested, the KDM5 
enzymes were completely inhibited and H3K4me3 lev-
els reached that of the cells transfected with the MUT 
KDM5 enzyme (Fig. 2a (i–iii), b). In line with the in vitro 
biochemical potency of the parent carboxylic acid 
(KDOAM-20), KDOAM-21 showed potent inhibition 
of H3K4me3 demethylation caused by overexpressed 
KDM5B with an EC50 < 1 µM. Surprisingly, KDOAM-20 
also showed activity against KDM5B in cells with an EC50 
of 20 µM despite having low cell permeability in Caco-2 
assays (Additional file 4: Table S2). The other KDM5 fam-
ily members tested (KDM5A, KDM5C and KDM5D) 
were also potently inhibited by KDOAM-21 with EC50 
values in the 3–5  μM range in line with the measured 
in vitro potency of the parent carboxylic acid KDOAM-
20 (Fig.  2b; Table  1), but showed little inhibition upon 
treatment with KDOAM-20 consistent with poor cell 
penetrance of the parent carboxylic acid (Additional 
file  4: Table S2). KDOAM-20/21 also showed inhibition 
of the KDM4 family, which was assessed by increase of 
the H3K9me3 mark. KDM4B was inhibited most potently 
with an EC50 value of 10  μM for KDOAM-21 (Fig.  2c; 
Table  1). For the KDM4 subfamily members tested, we 
also observed inhibition of the overexpressed enzymes 
by the compounds within the same potency rank order as 
observed in enzyme kinetic assays (Fig. 2c; Table 1; Addi-
tional file  4: Table S2). None of the inhibitors showed 
activity on members of the other demethylase families 
tested (KDM3A activity on H3K9me2, KDM6B activity 
on H3K27me3) (Fig. 2c; Table 1) consistent with the weak 
in  vitro enzymatic potency of these compounds versus 
the respective demethylase assays.
Interestingly, at higher KDOAM-20/21 inhibitor con-
centrations, a dose-dependent effect on the H3K4me3 
mark was observed in cells overexpressing MUT KDM5. 
This effect was not seen in cells expressing WT or MUT 
KDM5 treated with the control compound KDOAM-32, 
possibly indicating that the observed effects were either 
due to inhibition of the endogenous enzyme(s) or due 
to a nonspecific effect of KDOAM-21 and KDOAM-20 
(Fig.  2b). We observed no toxicity as measured by cell 
count using HeLa cells at any of the measured concen-
trations, indicated by a constant number of cells assessed 
in the high-content screen (Additional file  5: Figure 
S3). In order to further study inhibition of endogenous 
H3K4me3 levels, nontransfected HeLa cells were treated 
with KDOAM-20, KDOAM-21 and the inactive control 
KDOAM-32 at the same concentrations used in assays 
where the protein was ectopically expressed. H3K4me3 
was monitored after 72 h by IF staining. Observed EC50 
(sub-μM potency for KDOAM-21, ~50 μM for KDOAM-
20 and no inhibition observed for KDOAM-32) were in 
good agreement with EC50 values measured using the 
overexpressed enzyme (Fig.  2d; Table  1). Similar results 
were obtained after treatment of nontransfected HeLa 
cells for 48 h, whereas at 24 h the observed EC50 values 
were slightly lower (Hatch et al. unpublished results). We 
therefore have established a robust panel of cell assays to 
test inhibitors for the Jumonji family of KDMs.
Treatment of cells with inhibitors of the recently 
disclosed cell-penetrant cyanopyrazole class such as 
CPI-455 [28, 29] (Table  1; Additional file  3: Figure S2; 
Additional file 4: Table S2) resulted in a dose-dependent 
increase of the H3K4me3 mark (Fig. 3a). An increase in 
methylation in both WT and MUT KDM5-expressing 
cells was observed, which was even more pronounced 
than noted with KDOAM-21, as described above. No 
reduction in cell numbers was observed after treatment 
with this inhibitor, indicating that the compound is not 
toxic at the exposures examined (Fig.  3a). We hypoth-
esized that the observed CPI-455-dependent increase of 
the H3K4me3 mark in cells overexpressing the mutant 
KDM5B protein was due to compound-mediated inhibi-
tion of the endogenous KDM5 enzyme(s) as observed for 
the KDOAM series.
In the weakly acidic pyridopyrimidinone series [13] 
(Table 1; Additional file 3: Figure S2), we observed dose-
response cellular activity in the KDM5B IF assay. Treat-
ment with KDIPP51 (CCT364883) resulted in a marked 
spike indicating increased methylation levels in both 
(See figure on previous page.) 
Fig. 2 Immunofluorescence assay assessing and comparing potencies of inhibitors in cells. a Widefield fluorescence imaging of HeLa cells after 
dosing with inhibitor, fixing and staining with i, iv, vii DAPI (blue), ii, v, viii histone antibody for H3K4me3 (green), and iii, vi, ix a FLAG-tag antibody 
that demarcates cells overexpressing KDM5B (red). Cells overexpressing the wild-type (WT) KDM were treated with the inhibitor KDOAM-21 (i–iii) or 
with DMSO (iv–vi); controls cells overexpressing an inactive mutant (MUT) were treated with DMSO (vii–ix). Arrowheads indicate KDM overexpress-
ing cells. The scalebar represents 50 µm, b–d measurement of the average histone mark intensity in the transfected HeLa cells allows quantification 
of inhibitor potency against each target. KDOAM-21 (red), KDOAM-20 (blue) and the inactive control KDOAM-32 (black) were tested on multiple 
targets, b illustrates the characteristic dose–response curves of the potent KDOAM-21, weak KDOAM-20 and inactive KDOAM-32 compounds on 
KDM5 family members. The wild type (WT) and catalytically inactive mutant (MUT) of each target are shown as bold and dashed lines, respectively. 
The baseline for the mutant is of similar intensity as the nontransfected cells and approximately represents complete inhibition of the target dem-
ethylase activity, c selectivity of KDOAM-20 and KDOAM-21 against KDM5 is further demonstrated in cells by their weaker potency against other 
demethylases, i.e. members of the KDM3, KDM4 and KDM6 families. In d, KDOAM-21 and, to a lesser extent, KDOAM-20 are shown to have activity 
against endogenous KDMs as seen by changes in H3K4me3 in nontransfected cells. KDOAM-32 retains its inactivity
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WT and MUT KDM5B-expressing cells at the highest 
inhibitor concentration (Fig.  3b). This spike in methyla-
tion levels correlates with a steep drop in cell numbers 
(Fig. 3b). The potent inhibitor KDOAM-21 demonstrated 
that KDM5 inhibition per se is not toxic to HeLa cells, so 
the observed cell death is unlikely to be solely due to inhi-
bition of KDM5 demethylation activity. Cell permeabil-
ity for both compounds is good and better for KDIPP15 
compared to KDIPP51 (Additional file  4: Table S2). We 
therefore propose that the observed spike in H3K4 meth-
ylation is most likely due to nonspecific off-target effects 
of KDIPP51 and/or is due to the simultaneous inhibition 
of several KDMs. In cells overexpressing KDM5B and 
treated with the promiscuous KDM inhibitors IOX1 [30] 
and JIB-04 [16], we only observed cell toxicity at high 
concentrations (Fig. 4a; Additional file 6: Figure S4). Both 
of these inhibitors elicited a dose-dependent increase of 
H3K4me3 in cells transfected with WT KDM5B. In addi-
tion, treatment with the broad-spectrum KDM inhibi-
tor JIB-04 at concentrations above ~20  µM resulted in 
an increase of H3K4me3 in cells expressing either the 
WT or the MUT enzyme similar to what was observed 
with KDIPP51 in cells overexpressing KDM5B (Table 1; 
Fig. 4a) and accompanied by a reduction in cell number 
(Additional file 6: Figure S4).
The KDM6A/B inhibitor GSK-J4 [21] is reported to 
also inhibit KDM5 at higher concentrations in  vitro 
[31]. We tested GSK-J4 together with its inactive con-
trol compound GSK-J5 and also observed an increase 
of the H3K4me3 mark upon treatment with the active 
KDM6A/B inhibitor, but not the inactive control. These 
two compounds showed only minor toxicity at the high-
est concentrations used, which is well above the effective 
doses used for KDM6A/B inhibition (~1  µM) (Fig.  4b; 
Additional file 6: Figure S4). Assessment of inhibitors in 
the high-content assay therefore needs careful considera-
tion of all parameters, WT and MUT data. In addition, 
steep-slope increases of histone methylation mark are 
often accompanied by a reduction in cell number point-
ing to cell toxicity of the compound. The results imply 
that simultaneous inhibition of several KDMs does not 
seem to be tolerated at higher compound concentrations 
by the tested cells.
The observed spike in histone methylation at toxic 
compound concentrations prompted us to test the effect 
of agents that cause cytotoxicity by different mechanisms 
Fig. 3 Effect of different KDM5 inhibitors on histone tail methylation status in HeLa cells. a Immunofluorescence assays of cells transfected with 
KDM5B and treated with the indicated inhibitors CPI-455 and KDOAM-32, respectively. Effect on H3K4me3 methylation is shown to be dose 
dependent in the upper panel. Number of cells in 20 fields, based on DAPI staining, is shown in the lower panel, b immunofluorescence assays of 
cells transfected with KDM5B and treated with inhibitors KDIPP15 or KDIPP51, as indicated. The dose-dependent effect on H3K4me3 methylation is 
shown in the upper panel. Number of cells in 20 fields, based on DAPI staining, is shown in the lower panel
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but that are known not to be associated with KDM inhib-
itor activity (Additional file 7: Table S3). Accordingly, we 
treated HeLa cells with the DNA intercalator doxorubicin 
and the microtubule stabilizer paclitaxel and monitored 
the effect of these cytotoxic agents on H3K4me3 levels 
(Fig. 5a). Both these compounds induced cell death with 
the expected EC50 values as estimated from the number 
of cells remaining per field after fixation (Fig.  5b). Sur-
prisingly, paclitaxel also led to a dose-dependent increase 
of H3K4me3, whereas doxorubicin had no effect on this 
mark indicating that cell death can be associated with 
an increase in H3K4me3 without direct inhibition of 
demethylases (Fig.  5c). We then tested the influence of 
these two compounds on the other histone marks used 
to assess KDM activity (Fig.  5d). Both inhibitors had a 
profound effect on the repressive H3K27me3 mark. Con-
versely, H3K9me2 levels were not affected by cell death 
induced by paclitaxel, but showed some increase upon 
treatment with doxorubicin, although the effects were 
more variable. Globally, H3K36me2 levels were only mar-
ginally affected by cell death induced by either of the two 
inhibitors but individual cells could show a complete lack 
of this mark upon treatment (Additional file 8: Figure S5). 
Similar effects on histone methylation have been noted 
using other compounds causing cell death like the broad-
spectrum kinase inhibitor staurosporine (unpublished 
observation). None of the three compounds had any spe-
cific effect on inhibition of KDM4C, KDM5B or KDM6B 
in in  vitro demethylase assays (Additional file  7: Table 
S3), indicating that mechanisms inducing cytotoxicity 
can commonly affect global histone methylation marks.
To assess the mode of cell death caused by these 
compounds and by the tested KDM inhibitors in more 
detail, we performed a high-content-based triple stain-
ing protocol (Fig. 6). Cells were categorized into healthy 
cells (Hoechst staining only), apoptotic cells defined as 
Annexin V positive with or without Yo-Pro 3 uptake, or 
necrotic cells defined by Yo-Pro 3-positive Annexin V 
negative staining (Fig.  6a) [32]. After 24  h of treatment 
with doxorubicin, paclitaxel or the pan-kinase inhibi-
tor staurosporine, cell death occurred and was accom-
panied by the appearance of a predominant apoptotic 
staining, in line with their known mechanism of action. 
At higher concentrations the number of necrotic cells 
increased as monitored by a Yo-Pro 3-positive stain-
ing. In contrast, cells treated with DMSO were defined 
as ‘healthy’ and showed predominantly a negative stain-
ing for both Annexin V and Yo-Pro 3 (Fig. 6b). We then 
tested the different KDM inhibitors to assess their effect 
on cell viability in more detail. As expected, inhibitors 
of the KDOAM series (KDOAM-20, KDOAM-21 and 
KDOAM-32) did not induce cell death at any of the con-
centrations measured, above the level of DMSO nor did 
CPI-455 or KDIPP15 (Fig. 6c, d). However, treatment of 
HeLa cells with KDIPP51 (at 60  µM) for 24  h resulted 
in 40% apoptotic and 20% necrotic cells as compared to 
20% apoptotic and 2% apoptotic cells upon treatment 
with KDIPP15 (66  µM), similar to what was observed 
for DMSO-treated cells, indicating that the observed 
changes in methylation coincide with cell death accom-
panied by increased apoptosis and necrosis (Fig.  6e). In 
the same assay, the pan-KDM inhibitors IOX1 and JIB-04 
and its inactive control displayed little to no cell toxicity, 
with only a minor effect of JIB-04 on cellular viability at 
30 µM. However, both the KDM6B inhibitor GSK-J4 and 
its inactive control GSK-J5 (Additional file 9: Figure S6) 
showed about 60% necrotic cells at 50 µM concentration, 
which is well above the concentration required to inhibit 
KDM5/6 activity in cellular assays.
We have recently described the discovery of cell-pen-
etrant analogues of the pyridopyrimidinone KDIPP51 
as dual KDM4/5-subfamily inhibitors [11]. We have 
used the assays described herein to measure the cellular 
activity of these compounds and their matched negative 
control analogues that we report here for the first time. 
Treatment of HeLa cells with CCT365599 resulted in a 
Fig. 4 Effect of various KDM inhibitors described in the literature on 
KDM5B-mediated H3K4me3 methylation in HeLa cells. a Effect of Pan-
KDM inhibitors IOX1 [30] and JIB-04 E as well as inactive control com-
pound JIB-04 Z [16] on KDM5B-mediated H3K4me3 demethylation, b 
effect of KDM6A/B inhibitor GSK-J4 and inactive control compound 
GSK-J5 [21, 31] on KDM5B-mediated H3K4me3 demethylation. Data 
represent the average and SEM of at least 100 cells
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concentration-dependent increase of H3K9me3 and 
H3K4me3 levels, while treatment with the respective 
negative controls CCT366293 had no effect (Fig. 7a). No 
cytotoxicity was observed for these compounds at the 
concentrations used to assess H3K4me3 and H3K9me3 
demethylation (Fig. 7b, c), suggesting that in these cases 
the increase in methylation is due to inhibition of the cor-
responding demethylase. However, we notice for these 
compounds and the other compounds tested that there 
is a drop-off in potency between the biochemical assays 
and cellular activity ranging from 20- to 300-fold. This 
effect has been partly attributed to intracellular competi-
tion by high concentrations of the endogenous cofactor 
2-OG [33]. To examine this, we measured the potency of 
CCT365599 and CCT365523 in the biochemical assays 
in the presence of increasing concentrations of 2-OG 
(Fig. 7d). Consistent with these inhibitors being competi-
tive with the co-substrate, the potency of the compounds 
Fig. 5 Apoptosis induced by different mechanisms is accompanied by methylation mark changes. a Images of HeLa cells treated with 100 nM 
paclitaxel for 24 h and stained with DAPI and a specific antibody for H3K4me3. The phase contrast image is shown to the left, blue DAPI nuclear 
stain in the middle and yellow H3K4me3 to the right. Arrows indicate apoptotic cells lacking the H3K4me3 mark, b number of HeLa cells treated 
with doxorubicin or paclitaxel in a dose-dependent manner based on counting of 12 fields, c immunofluorescence assay showing the effect of 
doxorubicin or paclitaxel treatment on H3K4me3 mark, d immunofluorescence assay showing the effect of doxorubicin or paclitaxel treatment on 
H3K27me3 mark, H3K9me2 mark and H3K36me2 mark, respectively
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Fig. 6 Cytotoxic activity of different KDM inhibitors in live cells. a High-content images of HeLa cells treated with 100 nM paclitaxel for 24 h and 
stained with Annexin V (green) and Yo-Pro (red). Apoptotic cells were defined as Annexin V positive with or without Yo-Pro 3 uptake; necrotic cells 
were defined as Yo-Pro 3 positive; and healthy cells were defined as Annexin V and Yo-Pro 3 negative, b percentage of healthy, apoptotic and 
necrotic HeLa cells treated with doxorubicin, paclitaxel or staurosporine in a dose-dependent manner, c percentage of healthy, apoptotic and 
necrotic HeLa cells treated with KDM inhibitors of the KDOAM series  or CPI-455 for 24 h in a dose-dependent manner, c immunofluorescence assay 
showing the effect of doxorubicin or paclitaxel treatment on H3K4me3 mark, d percentage of healthy, apoptotic and necrotic HeLa cells treated 
with compounds of the KDIPP series for 24 h in a dose-dependent manner, e percentage of healthy, apoptotic and necrotic HeLa cells treated with 
KDIPP15 (66 µM) or KDIPP51 (60 µM) for 24 h. Results are shown as mean ± SD from triplicates of two independent experiments
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Fig. 7 Cytotoxic activity of different KDM inhibitors in live cells and 2-OG dependency of KDM inhibition in vitro. Immunofluorescence assays 
of cells transfected with KDM5B or KDM4A and treated with the newly developed inhibitors CCT365599 and CCT366293, respectively. Effect on 
H3K4me3 methylation is shown in the left panel in a dose-dependent manner and on H3K9me3 in the right panel. Number of cells in 20 fields, 
based on DAPI staining, is shown in b, c. Percentage of healthy, apoptotic and necrotic HeLa cells treated with CCT365599 and CCT366293, respec-
tively, in a dose-dependent manner, d IC50 values in dependency of different 2-OG concentrations determined in AlphaScreen assay for different 
KDMs
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shifts in the presence of 2-OG, leading to values in the 
3–5 μM range in the presence of physiologically relevant 
2-OG concentrations (1000 μM).
Discussion
Almost all currently available JmjC-KDM inhibitors 
act via metal chelation and compete with the 2-OG co-
substrate for binding at the active site. Poor cellular 
activity has been a problem; however, cell permeability 
is not the only reason for the poor cellular activities of 
the 2-OG competitive KDM inhibitors [11]. The results 
presented here further inform on the cellular activities 
of KDM inhibitors. They indicate that the currently used 
in  vitro assays may overestimate the cellular effects due 
to the use of lower than physiologically relevant 2-OG 
concentration.
A number of methods have been described to assess 
cellular activity of KDM inhibitors, each with advantages 
as well as disadvantages [20]. We have described a panel 
of cellular assays to assess the direct inhibition of KDMs 
as well as selectivity of KDM inhibitors in cultured 
human cells using a high-content-based overexpres-
sion system. We assessed several known KDM inhibitors 
as well as newly described inhibitors and demonstrate 
the usefulness of structure-matched inactive control 
compounds to assess effects related to specific KDM 
inhibition. In addition, the results obtained with overex-
pression of the MUT protein in combination with assess-
ment of cell numbers provide a useful guide to enzyme 
inhibition in cells, helping to identify on-target effects. 
It is now our observation across multiple compounds 
that, in our hands, a spike in histone mark methylation is 
characteristic of cytotoxicity. The results obtained using 
this system are in good agreement with data obtained 
assaying endogenous demethylases, but offer the addi-
tional advantage of distinguishing between a direct effect 
on KDM inhibition and changes to histone methylation 
upon induction of cell death.
Cell death observed upon treatment with toxic com-
pounds (e.g. doxorubicin or paclitaxel) resulted in a 
dose-dependent increase in histone methylation, in 
particular of the repressive H3K27me3 mark, but also 
of other marks such as H3K4me3 and H3K9me2. A 
recent study reported the induction of global changes 
in histone lysine and arginine methylation and altered 
expression of lysine demethylases upon treatment of 
human cancer cells with HDAC inhibitors pointing to 
a complex network of histone crosstalk [34]. Increased 
methylation of histone H3K27 associated with apopto-
sis induced by staurosporine has also been described in 
osteosarcoma cells, but the study did not examine any 
changes in dimethyl or trimethyl histone H3K4 and 
H3K9 [35].
Although not addressed in the current study, one can 
speculate regarding the underlying physiological mecha-
nisms of these histone mark changes in apoptosis and 
general cell death. Little is known about changes in his-
tone methylation upon induction of cell death in humans 
although a global decrease in histone acetylation has been 
observed during apoptosis [36, 37]. Loss of histone H3 
methylation at lysine 4 has, however, been shown to trig-
ger apoptosis in Saccharomyces cerevisiae [38]. In mela-
noma cells, short-term treatment (4 h) with doxorubicin 
decreased H3K4me3 methylation but did not have an 
effect on H3K27me3 [39]. Detailed chromatin immuno-
precipitation-based assays and gene expression analyses, 
as well as time-resolved experiments, will be necessary to 
investigate in more detail the interplay between cell death 
and chromatin changes addressing questions of specific 
mechanisms—for example, if cells first activate genes 
through increased density of H3K4me3 activating marks 
before increasing repressive marks like H3K27me3 when 
cell death cannot be avoided.
Conclusions
In summary, we have developed a series of overexpres-
sion IF assays to assess the target engagement of KDM 
inhibitors in cells. The presented assays cover most major 
branches of the 2-OG JmjC-KDMs. Nonspecific toxic-
ity of tested inhibitors, in particular those resulting in 
apoptosis, leads to changes in histone tail modifications 
unrelated to the expected cellular activity of these com-
pounds. The presented assay provides a suitable method 
to distinguish between direct and indirect effects of his-
tone methylation.
Methods
Cloning
Full-length cDNA for KDM5A (JARID1A, P29375), 
KDM5B (JARID1B, Q9UGL1, cDNA), KDM5C 
(JARID1C, P41229, IMAGE 5492114), KDM4A (O75164) 
containing A482E substitution (natural variant rs586339), 
KDM4B (JMJD2B, O94953, gift from ICR), KDM4C 
(JMJD2C, Q9H3R0, 8143862), KDM3A (JMJD1A, 
Q9Y4C1, 4823253), KDM2A (FBXL11, Q9Y2K7, 
5534384) and KDM6B (JMJD3, O15054, cDNA) were 
amplified by PCR from either a MGC clone or commer-
cial cDNA source or received as a gift from collaborators 
and cloned into pDONR-221 vector using Gateway BP 
reaction producing Gateway entry clones.
To produce catalytically inactive KDMs residues 
involved in iron coordination were substituted for ala-
nine (KDM5A H483A/E485A, KDM5B H499A/E501A, 
KDM5C H513A/E515A, KDM5D H510A/E512A, 
KDM4A H188A/E190A, KDM4B H189A/E191A, 
KDM4C H190A/E192A, KDM3A H1120Y, KDM2A 
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H212A/D214A and KDM6B H1390A/E1392A). Muta-
tions were introduced into full-length KDM Gateway 
entry clones using 15 cycles QuikChange II PCR protocol 
(Agilent Technologies).
Mammalian expression constructs encoding for N-ter-
minal 3*FLAG potencies were constructed using the 
Gateway LR recombination reaction between pCDNA5-
FRT/TO-3FLAG destination vector [40] and the wild-
type or mutated KDM Gateway entry clone.
All constructs described are available upon request.
Cell culture/transfection for 24‑h IF assay
HeLa cells (ATCC) were cultured at 37  °C and 5% CO2 
in Minimal Essential Media—Eagle (Sigma-Aldrich, 
UK) supplemented with 10% heat-inactivated foetal calf 
serum (FCS) (Gibco, UK), and 1% l-glutaMAX (Gibco, 
UK) in T75 flasks (Sarstedt, UK) and passaged regularly 
with TrypLE (Life Technologies, UK) before cells reached 
confluence. On day 0, 7000 cells per well were plated on 
a 96-well clear bottom CellCarrier plate (PerkinElmer, 
UK). The next day the cells were transfected with Lipo-
fectamine 3000 (ThermoFisher Scientific, UK) following 
the manufacturer’s instructions. Briefly, 0.1  µg of plas-
mid DNA (encoding for the respective demethylase) and 
0.15  µL of Lipofectamine 3000 were diluted in separate 
tubes containing 5 µL OptiMEM. 0.15 µL of P3000 was 
added to the tube with the DNA. The two solutions were 
then mixed gently and allowed to incubate for 5 min at 
room temperature. Next, the DNA-lipid complex was 
added to the cells for 4 h at 37 °C and 5% CO2.
Compound dilutions were made in a 96-well PCR plate 
(Starlab, UK). The culture medium was supplemented 
with 0.4% DMSO so that the solvent concentration 
was maintained throughout. Compounds were serially 
diluted at a 1:2 or 1:3 dilution ratio. Next, the cell culture 
plate was removed from the incubator and the medium 
was gently aspirated and replaced with the fresh medium 
containing diluted compounds.
After 24 h of compound incubation, cells were stained 
using the following protocol. First, the cells were washed 
once with Phosphate Buffered Saline (PBS) (Sigma-
Aldrich, UK) and fixed for 20 min at room temperature 
using formaldehyde diluted in PBS to 4% w/v. Next, cells 
were rinsed once with PBS and permeabilized for 5 min 
at room temperature using TritonX-100 diluted in PBS 
at 0.5% v/v. Then cells were rinsed once with PBS and 
blocked for 30  min at room temperature using 3% v/v 
foetal calf serum diluted in PBS. This mixture was then 
replaced with the appropriate primary antibodies for the 
histone mark and FLAG-tag diluted in blocking solu-
tion and left on overnight at 4 °C. The following day, cells 
were rinsed three times with PBS and stained with the 
secondary antibody for 1 h at room temperature. Before 
imaging, cells were rinsed once with PBS, stained with 
DAPI (LifeTechnologies, UK) for 5 min and rinsed again 
with PBS at room temperature.
Endogenous IF assay
The experimental set-up was similar to the 24-h assay 
except for the following modifications. Cells were cul-
tured in OptiMEM (LifeTechnologies, UK) and supple-
mented with 0.5% foetal calf serum (FCS) (Gibco, UK) 
and 1% l-glutaMAX (Gibco, UK). HeLa cells were seeded 
at a density of 800 cells per well on day 0. The next day, a 
compound dilution plate (diluted in OptiMEM with sup-
plements) was made and the medium from the day before 
replaced. The cells were incubated for 72 h at 37 °C and 
5% CO2. After fixation, the immunofluorescence proto-
col was similar as the 24-h assay with the omission of the 
FLAG-tag antibodies (Table 2). 
Widefield fluorescence microscopy
Transfection of cells was assessed on a Zeiss AxioObserver 
Z1 inverted fluorescence microscope fitted with an Axio-
cam 506 monochrome camera, Colibri.2 LED system (385, 
475, 561, 647 nm), 10× 0.45 N.A. and 20× 0.8 N.A. Plan 
Apochromat objectives. The system PC ran Windows 7 
Ultimate 64-bit and had an Intel Core i5-2500 @3.30 GHz 
processor with 8 GB RAM and an integrated video card. 
The microscope was controlled with ZEN Blue.
High‑content analysis
Immunofluorescence images of 20 fields (if not indicated 
otherwise) were captured through a 20× objective on a 
PerkinElmer Operetta or the GE IN Cell 6000 using the 
appropriate filters and light sources for exciting DAPI, 
Alexafluor 488, and Alexafluor 568 or Alexafluor 647. 
The images were imported into Columbus (PerkinElmer) 
for further analysis. From the DAPI channel, a binary 
mask was created to exclude individual nuclei smaller 
than 100 µm2 and those overlapping the edge of the field. 
The remaining nuclei were used for further analysis. The 
average nuclear intensity of the anti-Flag staining (Alex-
afluor 568 or Alexafluor 647) was measured, and then the 
intensity of the anti-methylated histone mark (Alexafluor 
488) was analysed only in those cells that strongly overex-
pressed the FLAG-tagged demethylase. The total number 
of nuclei was used as a measure of cell survival and to cal-
culate transfection efficiency. For the endogenous assay, 
the intensity of Alexafluor 488 from all cells in 9–10 fields 
was used for analysis. The average intensity and standard 
deviation of Alexafluor 488 cells was measured for each 
well and plotted in a dose-dependent manner in Prism 
(GraphPad, USA).
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Hoechst 33342/Yo‑Pro 3/Annexin triple staining and live 
cell death pattern analysis
Cells exposed to the inhibitors for 24 h were stained with 
Hoechst 33342 (1 µM), Yo-Pro 3 (1 µM) and Annexin V 
(0.3 μL per well) for 1 h. Cellular fluorescence was meas-
ured using the IN Cell 6000 (GE) using the following set-
up parameters: bright-field transmitted light at 50% for 
15 ms; Hoechst 33342 was excited by 35-ms exposure(Ex 
360–400  nm/Em 410–480  nm), Yo-Pro 3 by 35-ms 
exposure(Ex 560–580 nm/Em 650–760 nm) and Annexin 
V (Alexa 488) by 45-ms exposure(Ex 460–490  nm/Em 
500–550 nm). All the generated data were analysed using 
the IN Cell Analyser software, and three categories were 
distinguished: healthy cells, apoptosis and necrosis—cal-
culated as percentage of each class for every concentra-
tion used.
Caco‑2 permeability
Papp  (apparent permeability) was determined in the 
Caco-2 human colon carcinoma cell line essentially as 
described in [11].
AlphaScreen
IC50 values were determined as previously described [11]. 
The following amendments were made to the protocol 
for carrying out 2-OG competition assays.
For each compound, a 10  mM stock concentration in 
100% DMSO was used. Compounds (100  nL) were dis-
pensed with an ECHO® 550 acoustic dispenser (Labcyte 
Inc™, Sunnyvale, CA, USA) to generate 10–12  pt dilu-
tion curves directly into 384-well Proxiplates (#6008289, 
PerkinElmer, Waltham, MA, USA) to give final assay 
concentrations in the range 0.00015–30  µM in 2%(v/v) 
DMSO where appropriate. Compounds were pre-incu-
bated with their enzymes (2.5  µL, 1.5  nM KDM4A, 
0.5 nM KDM4B or for 2 nM KDM5B final assay concen-
tration) for 10 min at room temperature before the addi-
tion of their peptide substrates (2.5 µL).
Peptide substrates (60  nM ARTKQTARK(me3)STG-
GKAPRKQLA-GGK-biotin for KDM4A and KDM4B or 
200  nM ARTK(me3)QTARKSTGGKAPRKQLA-GGK-
biotin for KDM5B) were made up in peptide buffer 
consisting of HEPES (50  mM, pH 7.5), BSA (0.1%), 
sodium ascorbate (200  µM), ammonium iron(II) sul-
phate hexahydrate (2  µM for KDM4A/KDM4B and 
10  µM for KDM5B), Tween 20 (0.01%) and 11 2-OG 
concentrations ranging from 2000 to 0.5  µM. Peptide 
and buffer components were diluted twofold upon the 
addition to the compound plate containing enzyme in 
assay buffer [HEPES (50 mM, pH 7.5), BSA (0.1%) and 
Tween 20 (0.01%)]. The plate was sealed, then centri-
fuged at 1000 rpm for 1 min before being left for 15 min 
at room temperature. The reaction was stopped with 
the addition of 2.5 µL EDTA (30 mM EDTA in water for 
KDM4A and KDM4B or 30 mM EDTA, 1600 mM NaCl, 
50 mM HEPES pH 7.5 and 0.01% Tween 20 for KDM5B) 
before the addition of 2.5  µL AlphaScreen detection 
reagents and antibody appropriate for the substrate 
being detected (mouse IgG beads (#6760606M, Perki-
nElmer) and anti-dimethyl H3K9 antibody (#Ab1220, 
Abcam) for KDM4A and KDM4B and Protein A beads 
(#6760617M, PerkinElmer) and anti-dimethyl H3K4 
antibody (#9725S, Cell Signalling Technology) for 
KDM5B). AlphaScreen beads and antibody mixes were 
prepared and pre-incubated for 1  h prior to addition 
to the plate. Plates were left for 1.5 h in the dark before 
being read on the EnVision® Multilabel Reader (Perki-
nElmer Life Sciences). All assays were run at a final 
assay reaction volume of 5 µL and a total assay volume 
of 10 µL.
Data were normalized to the controls without 2-OG 
and DMSO wells containing all reagents as the totals. 
IC50 values at each 2-OG concentration were determined 
using a nonlinear regression fit of the log (inhibitor) ver-
sus response with variable slope equation in GraphPad 
Prism 6.0.
Table 2 Antibody specifications for each demethylase IF assay
Demethylase Histone 
mark
Primary antibody 
for histone mark 
(cat. no.)
Dilution Secondary anti‑
body for his‑
tone mark (cat. 
no.)
Dilution Primary anti‑
body for FLAG‑
tag (cat. no.)
Dilution Secondary anti‑
body for FLAG‑
tag (cat. no.)
Dilution
KDM3A H3K9me2 Abcam (ab1220) 1:500 Alexafluor 488 
(MG2A20)
1:500 F7425 1:500 A-11011 1:500
KDM4A/B/C H3K9me3 Abcam (ab8898-
100)
1:500 Alexafluor 488 
(A-11070)
1:500 F3165 1:500 A21124 1:500
KDM6B H3K27me3 Millipore (07-449) 1:500 Alexafluor 488 
(A-11070)
1:500 F3165 1:500 A21124 1:500
KDM5A/B/C H3K4me3 Diagenode 
(C15410003-50)
1:500 Alexafluor 488 
(A-11070)
1:500 F3165 1:500 A21124 1:500
Page 16 of 17Hatch et al. Epigenetics & Chromatin  (2017) 10:9 
Chemical synthesis
Additional file 10 Methods.
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